Our clinical development program is focused on improving the lives of cancer patients utilizing innovative approaches either in monotherapy or in combination with existing therapies.
Our most advanced program evaluating resminostat in patients with cutaneous T‑cell lymphoma (CTCL) is at the pivotal stage of development. The RESMAIN study is being conducted in more than 50 centers in 11 European countries.
SENSITIZE – Phase Ib/II study of 4SC-202 + checkpoint inhibitor pembrolizumab (Keytruda®, Merck) in melanoma
The SENSITIZE study will enroll 40 patients suffering from unresectable advanced-stage cutaneous melanoma who are refractory or non-responding to prior treatment with anti-PD-1 antibodies (checkpoint inhibitors). The study is being conducted at 6 certified skin cancer centers in Germany.
The addition of resminostat to the current standard of care – sorafenib – resulted in prolonged time till disease progression and a substantial benefit in median overall survival in a large subgroup of patients with a normal to high platelet count at study entry (50% of all patients in the study).
Patients in this subgroup treated with resminostat and sorafenib survived for 13.7 months as compared to 5.1 months for patients treated with sorafenib alone.
The Phase II trial evaluated the combination of sorafenib and resminostat versus sorafenib as first-line therapy in 170 patients with liver cancer (hepatocellular carcinoma, HCC) in Japan and Korea.